Promising Overall Survival And Progression-free Survival With VARGATEF(TM) (BIBF 1120) For Advanced, Relapsed Non-small Cell Lung Cancer

Monotherapy treatment with the triple angiokinase inhibitor1 BIBF 1120 (planned tradename VARGATEF?) offers promising efficacy and is well tolerated in patients with advanced, relapsed non-small cell lung cancer (NSCLC), according to results from a phase II study in patients with lung cancer2.

More: continued here

Filed under: Lung Cancer on May 15th, 2008